Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Acquisition Helps Millipore's Q4 Sales Grow 50 Percent

NEW YORK (GenomeWeb News) — Millipore yesterday said fourth-quarter revenues increased 50 percent as R&D spending rose 41 percent and profit leapt 1,700 percent.
Total receipts for the three months ended Dec. 31, 2006 increased to $383 million from $256 million year over year.
Compared with the fourth quarter of 2005, sales in the company’s Bioprocess segment was up 42 percent to $224 million, while its Bioscience segment gained 61 percent with sales of $158 million.
In a statement, CEO Martin Madaus attributed much of the growth to improved execution, BioProcess and Bioscience sales and acquisitions, including the purchase in July of Serologicals for $1.4 billion.
R&D spending increased to $23.9 million from $17 million year over year.
The company said profits increased to $18.5 million from $1 million in the year-ago period.
Millipore said it had around $77.5 million in cash and cash equivalents as of Dec. 31.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.